Aug 27 (Reuters) – The U.S. Food and Drug Administration has approved Gilead Sciences’ once-daily oral combination pill for treatment of adults whose HIV infection has already been reduced to very low levels, the company said on Thursday.
The drug, branded Bixlenvo, combines Gilead’s HIV medicines bictegravir and lenacapavir.
Bictegravir, the key component of the blockbuster treatment Biktarvy, is a widely recommended HIV drug with a high barrier to resistance.
Lenacapavir, marketed as Sunlenca for HIV treatment and as Yeztugo for HIV prevention, is a capsid inhibitor that targets the virus’s protective shell to disrupt its multiplication.
The human immunodeficiency virus (HIV) attacks the body’s immune system. Without treatment, it can lead to AIDS. There is currently no effective cure.
(Reporting by Kunal Das and Sneha S K in Bengaluru; Editing by Joyjeet Das)
Comments